MCL

Register now – June 26, 2025
PACE / State of FL
This webinar explores how artificial intelligence (AI) and digital pathology have the potential to revolutionize the clinical laboratory landscape. These technologies are transforming traditional laboratory practices by introducing advanced tools that enhance diagnostic and analytical capabilities. Digital pathology involves the digitization of pathology slides, allowing for more efficient storage, sharing, and analysis. AI, on the other hand, leverages machine learning algorithms to analyze complex data, providing faster and more accurate results. Together, they are setting new standards for precision diagnostics, early disease detection, and personalized medicine.

The following cases are designed for healthcare professionals interested in understanding the assessment and treatment options for patients with systemic lupus erythematosus disease.

In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by Russ Lebovitz, M.D., Ph.D., CEO and co-founder of Amprion. They discuss their strategic collaboration and the innovative SAAmplify™–αSYN (CSF) test.

In the first quarter of 2025, Mayo Clinic Laboratories expanded its test catalog with several innovative new tests.

Medical Laboratory Professionals Week is a time to appreciate the profound impact of laboratory medicine on healthcare and innovation.

Communication is a critical component of success. Laboratory outreach leaders can foster truly effective communication with five simple steps.

Learn why threshold diagnoses of the breast are important, how to approach them, and what role technology might play in the future.

Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' SPAS test identifies the form of arsenic present in patients with arsenic exposure. That information is important for determining the potential level of harm and for removing the patient from the arsenic source to ease symptoms and prevent cancer risk.

By using a test that measures neurofilament light chain (Nfl) proteins in blood, clinicians can better diagnose devastating diseases like ALS and MS, help predict disease progression, and better assess efficacy of existing drugs and trial therapies.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the recent court judgment on the U.S. Food and Drug Administration’s (FDA) oversight of lab-developed tests (LDT).

A compilation of interviews from previous episodes highlighting the pivotal role laboratory professionals play in healthcare. Featured interviews include Dr. Eric Hsi, Dr. Curt Hanson, and Jane Hermanson, all from Mayo Clinic in Rochester, Minnesota.

Due to severe weather affecting the FedEx hub in Memphis, Tennessee, delays are anticipated. The Mayo Clinic Laboratories’ Global Logistics team will be diverting work to other commercial shipping options.  

In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, invited Min-Han Tan, M.B.B.S., FRCP, Ph.D., founding CEO and medical director of Lucence, to discuss liquid biopsy cancer testing. Mayo Clinic Laboratories and Lucence recently announced a collaboration to expand access to this cutting-edge cancer test that is designed to detect clinically relevant biomarkers in ctDNA and ctRNA.